INS and Obesity: For obesity, drugs such as glucagon-like peptide-1 (GLP-1) receptor agonists promote satiety, reduce appetite, and enhance insulin secretion to stimulate weight loss, improve metabolism, and reduce cardiovascular disease (8–11).